JOHN P. NICHOLSON, M.D.; E. DARRACOTT VAUGHN, M.D.; THOMAS G. PICKERING, M.D.; LAWRENCE M. RESNICK, M.D.; JOSEPH ARTUSIO, M.D.; HOLLIS D. KLEINERT, Ph.D.; JORGE A. LOPEZ-OVERJERO, M.D.; JOHN H. LARAGH, M.D.
NICHOLSON JP, VAUGHN ED, PICKERING TG, RESNICK LM, ARTUSIO J, KLEINERT HD, et al. Pheochromocytoma and Prazosin. Ann Intern Med. 1983;99:477-479. doi: 10.7326/0003-4819-99-4-477
Download citation file:
Published: Ann Intern Med. 1983;99(4):477-479.
Prazosin was used to control the signs and symptoms of excessive alpha-adrenergic activity in four patients with pheochromocytomas. Long-term dosage requirements were predicted by the blood pressure response to a single 1-mg oral dose. However, surgical management of the pheochromocytomas was inadequate with prazosin alone, and intravenous phentolamine was required to suppress the pressor surges generated by the tumor during surgical manipulation and excision.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Hematology/Oncology, Adrenal Disorders, Endocrine Cancer.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only